Female Wellness

Regenerative medicine approaches, including platelet-rich plasma, or PRP, and cell-based products, are being studied for several distinct women’s health conditions. Research has examined these approaches in settings such as intrauterine scarring, vulvar lichen sclerosus, recurrent urinary tract infections, and premature ovarian insufficiency. These research settings are not interchangeable, and findings from one condition do not establish effectiveness for another.

What Researchers Are Studying

• Influence inflammation and tissue-repair processes in carefully selected conditions
• Be delivered safely and feasibly using local or targeted procedures
• Be further evaluated for condition-specific outcomes, such as symptoms, uterine measures, urinary infections, ovarian activity, or fertility outcomes
• Help identify which products, treatment methods, and patient groups warrant additional clinical study

PRP, cell-based products, and hormone therapy are distinct approaches. Research results can vary by diagnosis, product preparation, delivery method, background care, and the outcomes measured.

Note: PRP and stem cell therapies for women’s health are investigational and are not FDA-approved. Research findings do not guarantee individual results.

How Regenerative Medicine for Women’s Health Is Being Studied

Researchers are evaluating different products, doses, delivery methods, and treatment schedules. Studies assess safety, symptoms, quality of life, tissue measures, urinary-infection recurrence, ovarian activity, menstrual patterns, and fertility-related outcomes. This work is helping identify the approaches and patient groups that warrant continued clinical study. Stem cell treatment for female wellness remains investigational.

2025: UC-MSC Collagen Scaffold Reported Improved Endometrial Thickness and Pregnancy Outcomes in Refractory Asherman Syndrome

hUC-MSCs Loaded Collagen Scaffold for Refractory Thin Endometrium in Asherman Syndrome: A Double-Blind Randomized Trial — Read Study

This double-blind randomized trial evaluated umbilical-cord-derived MSCs placed on a collagen scaffold in women with refractory thin endometrium related to Asherman syndrome. The researchers reported improvements in endometrial thickness and pregnancy-related outcomes, including pregnancies and live births, compared with the control group. These findings add to growing clinical evidence that combining UC-MSCs with a collagen scaffold may help support endometrial repair and improve reproductive outcomes in some women with difficult-to-treat Asherman syndrome.

2025: Cord Blood PRP Reported Reduced Burning and Improved Sexual-Wellness Measures in Vulvar Lichen Sclerosus

First Use of Cord Blood Platelet-Rich Plasma in Vulvar Lichen Sclerosus: A Preliminary Study — Read Study

This preliminary study included 10 women with vulvar lichen sclerosus who received three cord-blood PRP injections. At three-month follow-up, the researchers reported that the treatment was well tolerated and was associated with improvements in burning symptoms as well as measures of sexual arousal and satisfaction. These early findings suggest that cord-blood PRP may help reduce discomfort and support sexual well-being in some women with vulvar lichen sclerosus, while providing a foundation for larger clinical studies.

2023: Intravesical PRP Reported Lower Recurrent UTI Frequency in Women

Effectiveness of Platelet-Rich Plasma Injections as Prophylaxis for Recurrent UTI in Women — Read Study

This study evaluated monthly PRP injections delivered directly into the bladder in women with recurrent urinary tract infections and compared outcomes with a group treated with antibiotics. During follow-up, the researchers reported fewer UTI recurrences in the PRP group. These findings add to early clinical evidence suggesting that intravesical PRP may help reduce the frequency of recurrent urinary tract infections in some women.

2020: UC-MSC Administration Reported Improved Ovarian Activity and Fertility-Related Outcomes in Premature Ovarian Insufficiency

Clinical Analysis of UC-MSC Allotransplantation in Premature Ovarian Insufficiency — Read Study

This clinical study included 61 women with premature ovarian insufficiency who received ultrasound-guided administration of umbilical-cord-derived MSCs directly into the ovaries. The researchers reported signs of renewed follicular activity and improvements in menstrual patterns, along with pregnancies and live births in some participants. These findings add to the clinical evidence suggesting that locally administered UC-MSCs may help support ovarian function and fertility-related outcomes in some women with premature ovarian insufficiency.

2018: UC-MSC Collagen Scaffold Reported Activated Ovarian Follicles and Pregnancy Outcomes in Premature Ovarian Failure

Transplantation of UC-MSCs on Collagen Scaffold Activates Dormant Ovarian Follicles in POF Patients — Read Study

This study evaluated umbilical-cord-derived MSCs delivered on a collagen scaffold in women with premature ovarian failure. The researchers reported signs of increased ovarian-follicle activity and changes in hormone-related measures, with pregnancies occurring in some participants. These findings add to early clinical evidence suggesting that scaffold-based UC-MSC treatment may help support ovarian activity and fertility-related outcomes in some women with premature ovarian failure.

For people seeking information about women’s health concerns, bioidentical hormone replacement therapy and other regenerative medicine approaches may be topics to discuss with a qualified healthcare provider. A consultation can help review your symptoms, diagnosis, current treatment plan, medical history, reproductive goals, and questions about the available research. You may also wish to discuss platelet-rich plasma (PRP) therapy with a clinician, since evidence and potential risks differ substantially by diagnosis and delivery method.

At Stemedix, we take a patient-centered approach to regenerative medicine, informed by emerging clinical research. Our team reviews your medical history, current treatment plan, and goals to help determine whether an investigational regenerative approach may be appropriate to explore.

This page is for educational purposes only and does not constitute medical advice.
PRP, stem cell, and other regenerative medicine therapies for women’s health are investigational and are not FDA-approved for this use. Research findings do not guarantee individual results.
Always consult a qualified healthcare professional before making treatment decisions.

1. Hou Z. et al. hUC-MSCs Loaded Collagen Scaffold for Refractory Thin Endometrium Caused by Asherman Syndrome: A Double-Blind Randomized Controlled Trial. Stem Cells Translational Medicine., 2025. PubMed
2. Boero V. et al. First Use of Cord Blood Platelet-Rich Plasma in the Treatment of Vulvar Lichen Sclerosus. Blood Transfusion., 2025. PubMed
3. Lee YK, Kuo HC. Effectiveness of Platelet-Rich Plasma Injections as Prophylaxis for Recurrent Urinary Tract Infection in Women. Journal of Clinical Medicine., 2023. PubMed
4. Zhang W. et al. Clinical Analysis of UC-MSC Allotransplantation in Premature Ovarian Insufficiency. Stem Cell Research & Therapy., 2020. Full Text
5. Ding C. et al. Transplantation of UC-MSCs on Collagen Scaffold Activates Dormant Ovarian Follicles in Patients With Premature Ovarian Failure. Stem Cell Research & Therapy., 2018. PubMed

U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. FDA